Literature DB >> 11487456

Tuberculosis Meningitis.

Thomas Byrd1, Phil Zinser.   

Abstract

Treatment of tuberculous meningitis should begin with an anti-tuberculous regimen of at least three drugs: isoniazid, pyrazinamide, and rifampin. Early in the course of therapy, ethambutol or streptomycin may be of some added benefit. If the local incidence of drug resistance to Mycobacterium tuberculosis is greater than 4%, or is unknown, then a fourth drug (ethambutol or streptomycin) should be added. If the patient is from an area with organisms resistant to multiple drugs, or is likely to be infected with a multiply resistant organism for any reason, then the patient should be on enough drugs to insure that at least two active anti-tubercular drugs are included in the therapy. An expert should be consulted Length of therapy is not standardized. For sensitive organisms, a regimen of three drugs daily for 2 months, followed by two-drug therapy (isoniazid and rifampin) has been recommended. The American Thoracic Society (ATS) and the Centers for Disease Control (CDC) have recommended a minimum of 12 months of therapy for tuberculous meningitis. If cultures remain positive for extended periods, or signs or symptoms respond slowly, therapy should be extended to 18 months. Patients with HIV also may need longer courses of therapy. The severity of tuberculous meningitis can be classified based on a system devised by the British Medical Research Council. Stage I patients are fully conscious, rational, and do not have neurologic signs. Stage II patients are confused or have neurologic signs such as cranial nerve palsy or hemiparesis. Stage III patients are comatose or stuporous with more severe neurologic signs. Corticosteroids are recommended if the patient is mentally confused, has neurologic signs, or is comatose (Stages II and III). In patients with moderate disease (Stage II), corticosteroids appear to improve neurologic sequelae and survival. Dexamethasone 6 to 12 mg per day and prednisone 60 to 80 mg per day tapered over 4 to 8 weeks has been used. Symptoms of central nervous system (CNS) inflammation may recur if the corticosteroid taper is implemented too soon or too fast. Steroids and diuretics such as furosemide and acetazolamide are sometimes used to treat hydrocephalus. Ventriculoperitoneal or ventriculoatrial shunting may be required to relieve signs and symptoms of hydrocephalus.

Entities:  

Year:  2001        PMID: 11487456     DOI: 10.1007/s11940-001-0030-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  11 in total

Review 1.  Central nervous system tuberculosis.

Authors:  J C Garcia-Monco
Journal:  Neurol Clin       Date:  1999-11       Impact factor: 3.806

2.  Tuberculous meningitis: correlation of therapeutic results with the pathogenesis and pathologic changes. II. Pathologic changes in untreated and treated cases.

Authors:  O AUERBACH
Journal:  Am Rev Tuberc       Date:  1951-10

Review 3.  Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature.

Authors:  D P Dooley; J L Carpenter; S Rademacher
Journal:  Clin Infect Dis       Date:  1997-10       Impact factor: 9.079

4.  Mycobacterium tuberculosis meningitis: a report of twelve cases and a literature review.

Authors:  W C Clark; J C Metcalf; M S Muhlbauer; F C Dohan; J H Robertson
Journal:  Neurosurgery       Date:  1986-05       Impact factor: 4.654

Review 5.  Antimycobacterial therapy.

Authors:  R E Van Scoy; C J Wilkowske
Journal:  Mayo Clin Proc       Date:  1999-10       Impact factor: 7.616

Review 6.  Management of tuberculosis meningitis.

Authors:  M R Holdiness
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

7.  Diagnosis and treatment of complicated tubercular meningitis.

Authors:  J J Kelly; E A Horowitz; C J Destache; A H Fruin; V A Long
Journal:  Pharmacotherapy       Date:  1999-10       Impact factor: 4.705

Review 8.  Should women taking antituberculosis drugs breast-feed?

Authors:  D E Snider; K E Powell
Journal:  Arch Intern Med       Date:  1984-03

Review 9.  Central nervous system tuberculosis: medical management and surgical indications.

Authors:  M R Gropper; M Schulder; A D Sharan; E S Cho
Journal:  Surg Neurol       Date:  1995-10

10.  Tuberculous meningitis: a 30-year review.

Authors:  S J Kent; S M Crowe; A Yung; C R Lucas; A M Mijch
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

View more
  2 in total

Review 1.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

2.  Prognostic factors of tuberculous meningitis: a single-center study.

Authors:  Jin Gu; Heping Xiao; Furong Wu; Yanping Ge; Jun Ma; Wenwen Sun
Journal:  Int J Clin Exp Med       Date:  2015-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.